What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Disease
His primary scientific interests are in Internal medicine, Surgery, Gastroenterology, Crohn's disease and Infliximab.
His Internal medicine study focuses mostly on Inflammatory bowel disease, Ulcerative colitis, Maintenance therapy, Crohn's Disease Activity Index and Azathioprine.
The various areas that Paul Rutgeerts examines in his Surgery study include Adalimumab, Placebo, Adverse effect and Clinical trial.
His Gastroenterology research incorporates themes from Chemotherapy, Certolizumab pegol, Vedolizumab, Colonoscopy and Corticosteroid.
Paul Rutgeerts has researched Crohn's disease in several fields, including Prospective cohort study, Severity of illness, Intestinal mucosa and C-reactive protein.
His studies deal with areas such as Pharmacokinetics, Predictive value of tests, Gastrointestinal agent, Management of Crohn's disease and Concomitant as well as Infliximab.
His most cited work include:
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (3357 citations)
- A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. (2837 citations)
- Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2790 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Gastroenterology, Crohn's disease, Immunology and Ulcerative colitis are his primary areas of study.
The concepts of his Internal medicine study are interwoven with issues in Placebo and Surgery.
His Gastroenterology study integrates concerns from other disciplines, such as Crohn's Disease Activity Index, Colectomy, Adverse effect and Colonoscopy.
His Crohn's disease research includes themes of Adalimumab, Azathioprine and C-reactive protein.
His Ulcerative colitis research is multidisciplinary, relying on both Golimumab and Colitis.
The study incorporates disciplines such as Gastrointestinal agent and Maintenance therapy in addition to Infliximab.
He most often published in these fields:
- Internal medicine (49.64%)
- Gastroenterology (38.86%)
- Crohn's disease (37.21%)
What were the highlights of his more recent work (between 2011-2021)?
- Internal medicine (49.64%)
- Gastroenterology (38.86%)
- Crohn's disease (37.21%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease.
His Internal medicine research integrates issues from Placebo and Surgery.
His Gastroenterology research incorporates elements of Mucosal healing, Adverse effect, Maintenance therapy, Vedolizumab and C-reactive protein.
His Crohn's disease research includes elements of Clinical trial and Ustekinumab.
His Ulcerative colitis study integrates concerns from other disciplines, such as Colonoscopy, Pharmacokinetics, Golimumab and Intestinal mucosa.
His study focuses on the intersection of Inflammatory bowel disease and fields such as Immunology with connections in the field of Drug.
Between 2011 and 2021, his most popular works were:
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease (1487 citations)
- Vedolizumab as induction and maintenance therapy for ulcerative colitis. (1388 citations)
- A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis (758 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Disease
His primary areas of study are Internal medicine, Gastroenterology, Ulcerative colitis, Inflammatory bowel disease and Surgery.
His Internal medicine study frequently links to related topics such as Placebo.
His studies deal with areas such as Odds ratio, Pharmacokinetics, Maintenance therapy, Confidence interval and Combination therapy as well as Gastroenterology.
He interconnects Colonoscopy, Golimumab and Intestinal mucosa in the investigation of issues within Ulcerative colitis.
His Inflammatory bowel disease research is multidisciplinary, relying on both Inflammation, Colitis, Immunology and Biopsy.
His Surgery research is multidisciplinary, incorporating perspectives in Crohn's Disease Activity Index and Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
